Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004

Yusuke Taira, Wataru Kudaka, Tomoko Nakamoto, Yoshihisa Arakaki, Yuko Shimoji, Natsuki Tamashiro, Masayuki Sekine